Peptilogics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Peptilogics, Inc. - overview
Established
2013
Location
Pittsburgh, PA, US
Primary Industry
Biotechnology
About
Founded in 2013 and based in Pittsburgh, US, Peptilogics, Inc. is a clinical-stage biotechnology company that develops engineered peptide therapeutics to treat life-threatening infections, including prosthetic joint and cystic fibrosis-related lung infections, using a proprietary AI-driven discovery platform. In October 2025, Peptilogics, Inc. raised USD 78 million in series B funding co-led by Thiel Bio, Presight Capital, Founders Fund, with participation from AMR Action Fund, Narya and Beyond Ventures.
Current Investors
BlueTree Venture Fund, AAF Management, CARB-X
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.peptilogics.com
Verticals
Artificial Intelligence, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.